8-K filing — INSULET CORP (PODD)
Filed: 2026-11-20 AccNo: 0001145197-26-000195 Size: 148 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stocks · News reference
Barclays analyst Christopher Pasquale maintained a 'Neutral' rating on Insulet Corporation while increasing the price target from $150 to $165.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-20 AccNo: 0001145197-26-000195 Size: 148 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
The global continuous ketone monitoring market is projected to grow from USD 18.5 million in 2025 to USD 5.48 billion by 2036, with a CAGR of 46.8%. Abbott leads the market as the first company to receive FDA and CE approvals for dual glucose-ketone sensors. Growth is driven by rising DKA incidence, SGLT2 inhibitor adoption, and integration with automated insulin delivery systems, though limited product availability and reimbursement uncertainty remain constraints.
Baird has downgraded Insulet Corporation to a Neutral rating, setting a price target of $158.
Stifel has downgraded Insulet Corporation to a Hold rating with a price target of $165.
Insulet Corporation and the Diabetes Leadership Council have launched the Patient Safety Net Protection (PSNP) Collaborative to advocate for the protection of healthcare access for individuals with diabetes.
Insulet Corporation has introduced a new global awareness campaign focused on the mental and emotional well-being of individuals living with diabetes.